Kayyem Jon Faiz

SEC Form 4 insider trading activity

Kayyem Jon Faiz has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Sep 8, 2026.

On the most recent filing, Kayyem Jon Faiz is listed as Director at Inhibrx Biosciences, Inc. Inside the rolling window, Kayyem Jon Faiz reported 1 open-market purchase totaling $568K in INBX and no open-market sales.

Companies traded

Other insiders at INBX

Insider Buying

$568K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
INBX
Kayyem Jon Faiz
Purchase$568KSep 8SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Kayyem Jon Faiz made?

Kayyem Jon Faiz has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.

Which companies does Kayyem Jon Faiz trade?

Kayyem Jon Faiz has filed SEC Form 4 disclosures for 1 company, including INBX.

When was Kayyem Jon Faiz's most recent SEC Form 4 filing?

Kayyem Jon Faiz's most recent SEC Form 4 filing on Tracefour is dated Sep 8, 2026.

What is Kayyem Jon Faiz's total buy and sell value in the current window?

Inside the rolling retention window, Kayyem Jon Faiz bought $568K and sold $0 based on SEC Form 4 filings.

What was Kayyem Jon Faiz's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 5,000 INBX shares on 2026-09-08, worth $568K, per SEC Form 4 filings.